{"nctId":"NCT01144338","briefTitle":"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2010-06-18","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":14752,"armGroups":[{"label":"Exenatide Once Weekly","type":"EXPERIMENTAL","interventionNames":["Drug: Exenatide Once Weekly"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Exenatide Once Weekly","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus\n* Patient has an HbA1c of ≥ 6.5 % and ≤ 10.0% and is currently using one of the following treatment regimens: A) Treatment with 0-3 oral antihyperglycemic agents B) Insulin therapy, either alone or in combination with up to two oral agents\n* Female patients must not be breast feeding and agree to use an effective method of contraception or must not otherwise be at risk of becoming pregnant.\n\nExclusion Criteria:\n\n* Patient has a diagnosis of type 1 diabetes mellitus, or a history of ketoacidosis.\n* Patient has ever been treated with an approved or investigational GLP-1 receptor agonist.\n* Patient is enrolled in another experimental protocol which involves the use of an investigational drug or device, or an intervention that would interfere with the conduct of the trial.\n* Patient has a planned or anticipated revascularization procedure.\n* Pregnancy or planned pregnancy during the trial period.\n* Patient has end-stage renal disease or an estimated glomerular filtration rate (eGFR) of \\<30 mL/min/1.73m2.\n* Patient has a history of gastroparesis or pancreatitis.\n* Personal or family history of medullary thyroid cancer or MEN2 (Multiple EndocrineNeoplasia Type 2) or calcitonin level of \\>40 ng/L at baseline.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Efficacy Outcome MACE Events","description":"The primary efficacy outcome variable is defined as the composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke. The number of participants who had an event is reported in the results.\n\nThe primary efficacy endpoint is the same as the primary safety endpoint, and the statistical analysis tests the superiority of exenatide against the placebo.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"905","spread":null},{"groupId":"OG001","value":"839","spread":null}]}]}]},{"type":"PRIMARY","title":"Primary Safety Outcome MACE Events","description":"The primary safety outcome variable is defined as the composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke. The number of participants who had an event is reported in the results.\n\nThe primary safety endpoint is the same as the primary efficacy endpoints, and the statistical analysis tests the non-inferiority of exenatide against placebo.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"905","spread":null},{"groupId":"OG001","value":"839","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Efficacy Outcome All-Cause Mortality","description":"The secondary efficacy outcome variable is defined as the all-cause mortality (deaths). The number of participants who had an event is reported in the results.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"584","spread":null},{"groupId":"OG001","value":"507","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Efficacy Outcome CV Death","description":"Component of the primary efficacy outcome: cardiovascular death. The number of participants who had an event is reported in the results.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"383","spread":null},{"groupId":"OG001","value":"340","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Efficacy Outcome MI","description":"Component of primary efficacy outcome: fatal or non-fatal MI. The number of participants who had an event is reported in the results.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"493","spread":null},{"groupId":"OG001","value":"483","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Efficacy Outcome Stroke","description":"Component of primary efficacy outcome: fatal or non-fatal stroke. The number of participants who had an event is reported in the results.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Efficacy Outcome Hospitalization for ACS","description":"The secondary efficacy outcome variable is defined as hospitalization for acute coronary syndrome. The number of participants who had an event is reported in the results.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"570","spread":null},{"groupId":"OG001","value":"602","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Efficacy Outcome Hospitalization for HF","description":"The secondary efficacy outcome variable is defined as hospitalization for heart failure. The number of participants who had an event is reported in the results.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null},{"groupId":"OG001","value":"219","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1222,"n":7372},"commonTop":[]}}}